Labiana |
17 September
Labiana, the Spanish pharmaceutical group specialised in the development, manufacture and commercialisation of medicines for animal and human health, will join the IBEX Growth Market 15, the index comprising the 15 BME Growth-listed companies with the highest free-float-adjusted market capitalisation among those meeting BME’s established liquidity requirements.
Labiana Nominated for ‘Best Sustainable Growth on BME Growth’ at the Estrategias de Inversión Awards
Labiana |
4 June
Labiana, the pharmaceutical group specialized in animal and human health and listed on BME Growth, has been nominated in the “Best Sustainable Growth on BME Growth” category at the second edition of the Estrategias de Inversión Listed Companies and Investment Funds Awards.
Labiana |
26 May
Labiana, returns once again to the Medcap Forum, the leading event for small- and mid-cap listed companies and institutional investors. Organized by BME, the forum will take place from May 26 to 28 at the Madrid Stock Exchange.
Labiana |
21 May
Labiana multiplied its profit by twelve in 2025 and reached €75.2 million in revenue, up 13.5%, with balanced growth, margin stability and lower net leverage.
Labiana |
20 May
Labiana participará en el Congreso Internacional ANEMBE 2026 en Valladolid, donde presentará sus últimas novedades en salud bovina y reafirmará su compromiso con la innovación, la calidad farmacéutica y el uso responsable de medicamentos veterinarios.
Labiana |
6 March
Labiana is publishing an informative guide to help its shareholders understand how subscription rights work and the different alternatives available during the capital increase.
